DermTech, Inc.

DermTech, Inc. (Nasdaq: DMTK), a molecular diagnostics company focused on non-invasive genomic testing for skin health and melanoma detection, completed its SPAC business combination in 2019 and began trading on Nasdaq under the ticker DMTK. Operating in the healthcare and diagnostics sector, DermTech built its platform around a proprietary Smart Sticker adhesive skin collection technology intended to reduce reliance on traditional surgical biopsies. On April 2, 2026, the company filed a Form 15-12G with the SEC, certifying the termination of its registration under Section 12(g) of the Securities Exchange Act of 1934, effectively ending its public reporting obligations. Sign up for full data, filings history, and status tracking on SpacDesk.